Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
A Phase I Study of XL119 (Rebeccamycin Analogue) in Combination With Oxaliplatin in Patients With Refractory Solid Tumors
Sponsor: National Cancer Institute (NCI)
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from National Cancer Institute (NCI)
Other Unspecified Adult Solid Tumor, Protocol Specific trials with similar outcome
- NCT04842630 · Phase PHASE1 · Nov 2022
- NCT01642342 · Phase PHASE1 · May 2019
- NCT02070406 · Phase PHASE1 · Dec 2018
- NCT01705106 · Phase PHASE1 · Feb 2016
- NCT02895490 · Phase NA · Oct 2015
Browse all Unspecified Adult Solid Tumor, Protocol Specific trials
A PHASE1 clinical study on Unspecified Adult Solid Tumor, Protocol Specific, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
May 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .